Status:
RECRUITING
Plasma Extracellular Vesicles in Meningioma Patients
Lead Sponsor:
University Hospital Heidelberg
Conditions:
Meningioma
Eligibility:
All Genders
Phase:
NA
Brief Summary
While surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenab...
Detailed Description
In total, 60 patients with meningiomas and an indication of radiotherapy (RT) and macroscopic tumor on the planning MRI will be enrolled. Blood samples will be obtained before the start, during, and a...
Eligibility Criteria
Inclusion
- confirmed meningioma (histologically or MRI/DOTATOC-PET CT)
- macroscopic tumor in MRI (either as definitive RT, or following subtotal resection or relapse)
- indication for radiotherapy
- completed wound healing after surgical intervention)
- Alter ≥ 18 Jahre
- Karnofsky Performance Score ≥ 60%
- written informed consent
- ability of subject to understand character and individual consequences of the trial
- adequate contraception for women of childbearing potential
Exclusion
- previous or known tumor diseases \< 5 years ago
- previous (cerebral) radiotherapy
- simultaneous chemo/immunotherapy
- evidence that the patient cannot adhere to the study protocol (e.g., non-compliance)
- the refusal of patients to participate in the study
- participation in another clinical study or observation period in a competing trial
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06104930
Start Date
November 1 2023
End Date
February 1 2026
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Heidelberg, Radiation Oncology
Heidelberg, Germany, 69120